Lupin Limited Fundamental Company Report Including Financial, Business, Recent Development, Industry Overview, Competitors and Key Risk Analysis
Lupin Limited is a Mumbai based transnational pharmaceutical company that produces generic & branded formulations and APIs for the developed and developing markets of the world. The company got incorporated in1968 as a manufacturer of Tuberculosis drugs. Over the years, the company has moved up the value chain and has not only mastered the business of intermediates and APIs, but has also leveraged its strengths to build a formidable formulations business globally.
Today the company sells its products in more than 70 across the world. It is among the top 10 players of US and Japan market- which are the two fastest growing drug market of the world. The company is the fastest growing pharmaceutical players in India and also the fastest growing Generic player in South Africa.
Lupin has manufacturing facilities in India as well as in Japan. In India the manufacturing facilities are located in Goa, Tarapur, Ankleswar, Jammu, Indore, Aurangabad and Mandideep. These facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and MCC South Africa.
Today the company sells its products in more than 70 across the world. It is among the top 10 players of US and Japan market- which are the two fastest growing drug market of the world. The company is the fastest growing pharmaceutical players in India and also the fastest growing Generic player in South Africa.
Lupin has manufacturing facilities in India as well as in Japan. In India the manufacturing facilities are located in Goa, Tarapur, Ankleswar, Jammu, Indore, Aurangabad and Mandideep. These facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and MCC South Africa.
1. SYNOPSIS
2. FINANCIAL PERFORMANCE
3. RECENT DEVELOPMENTS (JAPAN CRISIS AND LUPIN)
4. BUSINESS
5. INDUSTRIAL OVERVIEW
6. FINANCIALS
7. OUT LOOK & CONCLUSION/ VALUATION
8. PEER COMPARISON
9. KEY RISKS
2. FINANCIAL PERFORMANCE
3. RECENT DEVELOPMENTS (JAPAN CRISIS AND LUPIN)
4. BUSINESS
5. INDUSTRIAL OVERVIEW
6. FINANCIALS
7. OUT LOOK & CONCLUSION/ VALUATION
8. PEER COMPARISON
9. KEY RISKS
